东富龙科技集团股份有限公司 2024 年第三季度报告 证券代码：300171 证券简称：东富龙 公告编号：2024-040 东富龙科技集团股份有限公司 2024 年第三季度报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 东富龙科技集团股份有限公司 2024 年第三季度报告 会计政策变更 会计政策变更的原因及会计差错更正的情况 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------- ...

Financial Performance - Revenue for the reporting period was RMB 2.29 billion, a decrease of 22.36% compared to the same period last year[15] - Net profit attributable to shareholders of the listed company was RMB 113.97 million, a decrease of 73.25% year-on-year[15] - Net cash flow from operating activities was RMB 191.97 million, a significant increase of 161.40% compared to the same period last year[15] - Basic earnings per share (EPS) were RMB 0.1498, a decrease of 73.44% year-on-year[15] - Weighted average return on equity (ROE) was 1.44%, down 4.13 percentage points from the same period last year[15] - Total assets at the end of the reporting period were RMB 12.91 billion, a slight increase of 0.11% compared to the end of the previous year[15] - The company achieved revenue of approximately 2.291 billion yuan in the first half of 2024, a decrease of 22.36% compared to the same period in 2023[39] - Net profit attributable to the parent company in the first half of 2024 was approximately 114 million yuan, a decrease of 73.25% year-on-year[39] - Revenue decreased by 22.36% to 2,290,913,300.80 yuan, primarily due to slower fixed asset investment by downstream customers[42] - Net cash flow from operating activities increased by 161.40% to 191,968,271.79 yuan, driven by higher cash receipts from sales and reduced payments for goods and taxes[42] - R&D investment decreased by 6.24% to 153,918,552.97 yuan, mainly due to stricter project management and reduced material costs[42] - The Formulation Division's revenue decreased by 20.36% to 1,259,013,745.93 yuan, with a gross margin of 31.41%[43] - The Bioprocess Division's revenue decreased by 32.73% to 538,395,099.18 yuan, with a gross margin of 29.86%[43] - Domestic revenue decreased by 24.11% to 1,798,061,366.65 yuan, while international revenue decreased by 15.21% to 492,851,934.15 yuan[43] - Investment income was 9,902,341.40 yuan, accounting for 6.98% of total profit, mainly from interest income and long-term equity investment gains[44] - Accounts receivable increased by 1.09% to 1,658,758,801.81 yuan, due to higher new receivables from revenue recognition compared to collections[46] - Inventory decreased by 1.10% to 3,472,349,676.25 yuan, driven by improved order delivery management and reduced obsolete stock[46] - Fixed assets increased by 1.07% to 955,500,284.08 yuan, mainly due to the transfer of the second phase of the pharmaceutical equipment manufacturing base project[46] - The company's total investment in the reporting period was RMB 246,737,130.73, a 2.59% increase compared to the same period last year[49] - The company's financial assets at fair value totaled RMB 819,794,548.08, with a fair value change gain of RMB 8,675,877.99 during the period[47] - Restricted monetary funds at the end of the reporting period amounted to RMB 34,155,364.53, primarily due to performance bonds, litigation frozen funds, and restricted overseas funds[48] - The company has cumulatively invested RMB 300,992.25 million in raised funds, with RMB 23,496.12 million invested during the reporting period[49] - The company invested RMB 5,597.90 million in the biopharmaceutical equipment industry trial center project using funds raised from specific object issuance[49] - The company invested RMB 12,124.29 million in the Jiangsu biopharmaceutical equipment industrialization base project using funds raised from specific object issuance[49] - The company invested RMB 5,773.93 million in the Zhejiang Dongfulong Biotechnology Co., Ltd. life science industrialization base project using funds raised from specific object issuance[50] - The aseptic freeze-drying pharmaceutical equipment system integration industrialization project has achieved a cumulative investment of RMB 16,037.8 million, with an investment progress of 54.18%[51] - The biopharmaceutical equipment industry trial center project has achieved a cumulative investment of RMB 12,990.55 million, with an investment progress of 24.51%[51] - The Jiangsu biopharmaceutical equipment industrialization base project has achieved a cumulative investment of RMB 28,916.33 million, with an investment progress of 46.64%[51] - Acquired Shanghai Dianfan Medical Technology Co., Ltd. and increased capital by 3,000 million RMB, holding 100% ownership[52] - Acquired Shanghai Ruipai Machinery Co., Ltd. and increased capital by 4,895 million RMB, holding 100% ownership[52] - Purchased a building in Yigu·Modern Business Park (Phase II) for 2,659.72 million RMB, holding 100% ownership[52] - Purchased a building in Wuhan Jiulong Bio-Industry Base Bio-Pharmaceutical Industrial Park Accelerator Phase II for 1,638.6 million RMB, holding 99.68% ownership[52] - Increased capital in Shanghai Dongfulong Intelligent Control Technology Co., Ltd. by 9,900 million RMB, holding 100% ownership[52] - Established Shanghai Dongfulong Medical Technology Industry Development Co., Ltd. with an investment of 50,000 million RMB, holding 100% ownership[52] - Acquired 40% equity of Shanghai Yufa Pharmaceutical Co., Ltd. for 3,600 million RMB, holding 100% ownership[52] - Increased capital in Shanghai Dongfulong Pharmaceutical Equipment Manufacturing Co., Ltd. by 37,000 million RMB, holding 100% ownership[52] - Total over-raised funds used amounted to 143,412.28 million RMB, with actual usage of 143,407.08 million RMB[57] - The pharmaceutical equipment container manufacturing base project (Phase I) did not meet expected profits due to relatively low gross margins in basic manufacturing[53] - Company used 36.1 million yuan of over-raised funds to increase its stake in Shanghai Chenghuan Light Industry Machinery Co., Ltd. to 51%[58] - Company used 22.5 million yuan of over-raised funds to acquire 15% equity in Shanghai Dongfulong Dehui Air Conditioning Equipment Co., Ltd., making it a wholly-owned subsidiary[58] - Company plans to use 370 million yuan of over-raised funds to invest in the construction of a biopharmaceutical system equipment industrialization project through its wholly-owned subsidiary Shanghai Dongfulong Pharmaceutical Equipment Manufacturing Co., Ltd.[58] - Company changed the implementation location of the "Aseptic Freeze-drying Pharmaceutical Equipment System Integration Industrialization Project" from No. 1509, Duhui Road, Minhang District, Shanghai to No. 139, Duhui Road, Minhang District, Shanghai[58] - Company used 17.51 million yuan of raised funds to replace self-raised funds previously invested in the pharmaceutical equipment container manufacturing base construction project (Phase I)[58] - Company used 173.81 million yuan of raised funds to replace self-raised funds previously invested in the 2022 specific object issuance project[58] - Company completed the replacement of 347.61 million yuan of raised funds for pre-paid issuance fees and self-raised funds invested in the 2022 specific object issuance project[58] - The pharmaceutical equipment container manufacturing base construction project (Phase I) had a net surplus of 45.93 million yuan after deducting unpaid quality assurance funds and balances[58] - The company saved part of the planned equipment purchase funds by using its own funds to purchase equipment in advance, resulting in a net surplus of 135.29 million yuan for the "Aseptic Freeze-Drying Pharmaceutical Integration Project"[59] - The "Aseptic Freeze-Drying Pharmaceutical Integration Project" had an actual investment of 160.71 million yuan, accounting for 54.29% of the committed investment amount[59] - The company transferred 165.31 million yuan of surplus funds from the "Aseptic Freeze-Drying Pharmaceutical Integration Project" to the over-raised funds account for management and use in main business development and related industrial investments[59] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.19%/3.2981%[60] - The company used 24 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.20%/2.4324%[60] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.19%/2.4433%[60] - The company used 24 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.20%/2.4218%[60] - The company used 26 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.29%/2.4315%[60] - The company used 43 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.30%/2.7304%[60] - The company used 47 million yuan to purchase a structured deposit from Bank of China with an expected annualized yield of 1.29%/2.7402%[60] - The company purchased a structured deposit of 20 million yuan from Ningbo Bank with an expected annualized return rate of 1.0000%-3.0000%, earning a profit of 299,178.08 yuan[61] - The company purchased another structured deposit of 30 million yuan from Ningbo Bank with an expected annualized return rate of 1.5%-2.8%[61] - The company transferred 4.375 million shares at a price of 35 million yuan, which was returned to the over-raised funds account[61] - The total amount of entrusted wealth management during the reporting period was 653.6561 million yuan, with 526.1561 million yuan not yet due[63] - Shanghai Hanou subsidiary achieved a net profit of 21.7776 million yuan, contributing significantly to the company's overall performance[67] - Dongfulong Medical subsidiary reported a net loss of 17.2898 million yuan, impacting the company's overall profitability[67] - The company faces risks from intense industry competition and is focusing on upgrading manufacturing and expanding international markets to mitigate these risks[69] - Economic cycle and market demand fluctuations pose risks, and the company is maintaining flexible production and supply chains to adapt to market changes[69] - The company is actively pursuing external mergers and acquisitions to accelerate growth in bioprocessing and food equipment engineering, which may increase management risks[69] - Internal management risks are heightened due to industry transformation, and the company is improving organizational models and management levels to meet market demands[69] - The company's actual controller, Zheng Xiaodong, increased his shareholding by 1,770,000 shares, accounting for 0.23% of the total shares, with a total investment of 30,025,652 yuan (excluding transaction fees)[74] - The company implemented a 2023 equity distribution plan, distributing 2.391867 yuan per 10 shares, totaling 182,306,270.32 yuan (including tax)[74] - The company completed a share repurchase of 4,980,001 shares, accounting for 0.6503% of the total shares, with a total repurchase amount of 63,943,727.13 yuan (excluding transaction fees)[74] - The company's 2023 annual general meeting had a 61.44% investor participation rate[76] - The company is focusing on internationalization, digitalization, and systemization, with continuous investment in R&D and technological cooperation in the biopharmaceutical industry[74] - The company is strengthening its management structure and internal control systems to improve operational standards[74] - The company is actively engaging with investors through hotlines and interactive platforms, and held an annual performance briefing after the 2023 annual report[75] - The company is addressing exchange rate risks by using financial tools, optimizing settlement methods, and enhancing the recruitment and training of financial professionals[70] - The company is mitigating investment impairment risks by strengthening post-investment management and strategic alignment with acquired companies[70] - The company is enhancing human resource management by building a learning organization and training platforms to support employee growth and value creation[70] - The company adjusted the number of incentive recipients for the 2021 restricted stock incentive plan from 383 to 368, with the total number of restricted shares remaining at 20 million[78] - The company granted 300,000 restricted shares to 19 incentive recipients at a price of 9.47 yuan per share on December 3, 2021, with 1.915 million reserved shares becoming invalid[78] - In the first vesting period of the 2021 restricted stock incentive plan, 7.078 million shares were vested by 352 recipients, with the shares becoming tradable on May 20, 2022[78] - In the first vesting period of the reserved portion of the 2021 restricted stock incentive plan, 108,000 shares were vested by 17 recipients, with the shares becoming tradable on January 20, 2023[79] - In the second vesting period of the 2021 restricted stock incentive plan, 5.1795 million shares were vested by 336 recipients, with the shares becoming tradable on May 29, 2023[80] - In the second vesting period of the reserved portion of the 2021 restricted stock incentive plan, 72,000 shares were vested by 15 recipients, with the shares becoming tradable on December 22, 2023[80] - In the third vesting period of the 2021 restricted stock incentive plan, 4.9875 million shares were vested by 311 recipients, with the shares becoming tradable on May 23, 2024[80] - The company has provided over 10,000 pharmaceutical equipment and systems to nearly 3,000 well-known pharmaceutical companies in more than 50 countries and regions globally[82] - The company has held investor meetings, conference calls, and roadshows, receiving recognition from the capital market and investor relations community[84] - Since its listing in 2011, the company has conducted annual equity distributions, providing stable returns to investors[84] - The company has established a comprehensive quality management system based on ISO9001, integrating ICHQ9 quality risk management and GMP standards to enhance customer satisfaction[86] - Products are designed for the pharmaceutical, food, and medical industries, utilizing 304 or 316L stainless steel materials and advanced SCADA systems for automation[86] - The company invests millions annually in environmental protection and energy conservation, including the use of solar power to reduce electricity consumption[88] - A robust EHS (Environment, Health, and Safety) system is in place, with regular environmental inspections and emergency response drills[87] - The company actively participates in social welfare activities, including educational support, poverty alleviation, and disaster relief efforts[88] - Employee benefits include comprehensive insurance, housing, meals, and annual health check-ups, with additional support for families in need[85] - The company adheres to strict labor laws, ensuring all employees are paid above the Shanghai minimum wage and receive annual performance-based bonuses[85] - Supplier relationships are managed through annual and strategic cooperation agreements, with a focus on quality and mutual development[86] - The company has implemented green manufacturing practices, such as using environmentally friendly refrigerants and energy-efficient compressors[86] - The company's commitment to sustainability includes regular updates to environmental policies and active participation in community environmental initiatives[87] - The company's total shares increased from 760,774,540 to 765,762,040 due to the third vesting period of the 2021 restricted stock incentive plan, with 4,987,500 shares issued[104] - The company's actual controller, Zheng Xiaodong, increased his holdings by 1,420,000 shares during the reporting period, with 1,065,000 shares locked under the 75% lock-up rule[105] - The company plans to repurchase shares worth between 50 million yuan and 100 million yuan, with an estimated repurchase of 2.14 million to 4.28 million shares, accounting for 0.28% to 0.56% of the total shares[105] - The company leased properties in Hangzhou, Shanghai, and Jinshan, including office spaces and land use rights, but none of these leases contributed more than 10% of the company's total profit[100] - The company's restricted shares increased by 1,656,750 shares, bringing the total restricted shares to 203,170,685, accounting for 26.53% of the total shares[104] - The company's unrestricted shares increased by 3,330,750 shares, bringing the total unrestricted shares to 562,591,355, accounting for 73.47% of the total shares[104] - The company repurchased 4,980,001 shares, accounting for 0.6503% of the total shares, with a total repurchase amount of RMB 63,943,727.13[106] - The repurchase price ceiling was adjusted from RMB 23.35 per share to RMB 23.11 per share due to the 2023 annual equity distribution[106] - The company's total shares increased from 760,774,540 to 765,762,040 after the listing of 4,987,500 restricted shares from the 2021 restricted stock incentive plan[106] - The total number of restricted shares held by executives increased from 201,513,935 to 203,170,685[108] - The largest shareholder, Zheng Xiaodong, holds 34.08% of the shares, with 195,719,256 shares under lock-up[109] - The second-largest shareholder, Zheng Keqing, holds 16.41% of the shares, with all 125,667,408 shares being freely tradable[109] - The top 10 shareholders include Shanghai Biopharmaceutical Industry Equity Investment Fund and SDIC Innovation Investment Management, each holding 3.17% of the shares[109] - The top 10 shareholders also include Shanghai Junhe Licheng Investment Management Center, holding 1.90% of the shares[109] - The top 10 shareholders include Gaoyi Asset Management Partnership, holding 1.88% of the shares[111] - The top 10 shareholders include Hong Kong Securities Clearing Company, holding 1.83% of the shares[111] - The company's monetary funds at the end of the

东富龙（300171）2023 年年报&2024 年一季报点评 西南证券研究发展中心 上海 地址：上海市浦东新区陆家嘴 21 世纪大厦 10 楼 邮编：200120 北京 地址：北京市西城区金融大街 35 号国际企业大厦 A 座 8 楼 邮编：100033 深圳 地址：深圳市福田区益田路 6001 号太平金融大厦 22 楼 邮编：518038 重庆 地址：重庆市江北区金沙门路 32 号西南证券总部大楼 21 楼 邮编：400025 西南证券机构销售团队 | --- | --- | --- | --- | --- | --- | |-------|----------------------------|----------------------|--------------|-------------|----------------------| | 区域 | [Table_SalesPerson] 姓名 | 职务 | 座机 | 手机 | 邮箱 | | | 蒋诗烽 | 总经理助理、销售总监 | 021-68415309 | 18621310081 | jsf@swsc.com.cn | | | 崔露文 | ...

证券代码：300171 证券简称：东富龙 公告编号：2024-025 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 1.董事会、监事会及除之外的董事、监事、高级管理人员保证季度报告的真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 □是 否 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 否 1 | --- | --- | |---------------------------------------------|----------| | 是 □ 否 | | | | 本报告期 | | 支付的优先股股利（元） | 0.00 | | 支付的永续债利息（元） | 0.00 | | 用最新股本计算的全面摊薄每股收益（元 / 股） | 0.0850 | | --- | --- | --- | |------------------------------------------------------------------------------------------------------------- ...

八、非经常性损益项目及金额 □适用 不适用 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常 性损益项目界定为经常性损益项目的情况说明 东富龙科技集团股份有限公司 2023 年年度报告全文 公司的主营业务为制药装备的研发、生产、销售和技术服务等。根据中国证监会颁布 的《上市公司行业分类指引》（2012 年修订），公司属于专用设备制造业（分类代码： C35）。根据国家统计局颁布的《国民经济行业分类》国家标准（GB/T4754-2017），公司 属于专用设备制造业（分类代码：C35）中的印刷、制药、日化及日用品生产专用设备制 造（分类代码：C354）项下的子行业制药专用设备制造（分类代码 C3544）。 （2）制药装备行业发展现状 东富龙科技集团股份有限公司 2023 年年度报告全文 3、制药装备行业发展趋势 （3）模块化和定制化：制药装备行业越来越倾向于模块化设计和定制化生产。模块 化设计可以提高设备的灵活性和可维护性，同时也方便根据客户需求定制生产。这种趋势 使得制药企业能够更好地满足市场需求，提高竞争力。 东富龙科技集团股份有限公司 2023 年年度报告全文 二、报告期内公 ...

证券代码：300171 证券简称：东富龙 东富龙科技集团股份有限公司投资者关系活动记录表 编号：2023-005 □特定对象调研 □分析师会议 投资者关系活动 □媒体采访 □业绩说明会 类别 □新闻发布会 □路演活动 □现场参观 ■其他 电话会议 参与单位名称 电话通讯方式与会名单请见附件 及人员姓名 时间 2023年10 月27日 8：30—9：30 地点 电话会议 副总经理兼董事会秘书：王艳 上市公司接待 财务总监：陆德华 人员姓名 投资总监：张盟 1、公司 2023年前三季度经营情况介绍 答：2023年前三季度公司实现营业收入43.25 亿元，较 上年同期增长 13.31%，归属于上市公司股东的净利润 5.83 亿元，较上年同期减少 3.48%， 归属于上市公司扣非后净 利润 5.39亿元，较上年同期减少4.84%。 ...

证券代码：300171 证券简称：东富龙 公告编号：2023-047 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季 度报告中财务信息的真实、准确、完整。 1 （一） 主要会计数据和财务指标 | --- | --- | --- | --- | --- | |---------------------------------------|-------------------|-------------------------|-------------------|---------------------------| | | 本报告期 | 本报告期比上 年同期增减 | 年初至报告期末 | 年初至报告 期末比上年 | | 营业收入（元） | 1,374,336,583.25 | -1.13% | 4,325,047,311.88 | 同期增减 13.31% | | 归属于上市公司股东的 | 157,332,998.22 | -22.04% | 583,404,859.76 | ...

证券代码：300171 证券简称：东富龙 | --- | --- | |----------------|-----------------------| | | □特定对象调研 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | □现场参观 ■其他 电话会议 参与单位名称 及人员姓名 电话通讯方式与会名单请见附件 时间 2023 年 8 月 29 日 8：30—9：30 地点 电话会议 董事长兼总经理：郑效东 上市公司接待 财务总监：郜志坚 人员姓名 副总经理兼董事会秘书：王艳 投资总监：张盟 1、公司 2023 年半年度经营情况介绍。 答：2023 年半年度公司实现营业收入 29.51 亿元，较上年同期 增长 21.58%，归属于上市公司股东的净利润 4.26 亿元，较上年同期 增长 5.82%，归属于上市公司扣非后净利润 3.93 亿元，较上年同期 增 5.72%。国内收入 23.69 亿元，占比 80.3%；国际收入 5.81 亿元， 投资者关系活动主 占比 19.7%，国际占比与上年度相比有小幅度增长。 要内容介绍 2、请公司解读公司毛利率降低的原因 ...

委托理财出现预期无法收回本金或存在其他可能导致减值的情形 （2） 衍生品投资情况 □适用 不适用 □适用 不适用 公司报告期未出售重大资产。 适用 □不适用 适用 □不适用 九、公司控制的结构化主体情况 报告期内，制药行业变革加速，推动国内制药装备行业转型升级，行业集中度提升， 竞争日益激烈。公司主营业务盈利能力存在下滑的风险。 应对措施：公司将围绕着发展战略，完善包括投资项目尽职调查、可行性分析、投资 项目决策、子公司运行等各种管理制度，进行科学决策，提高公司治理水平，有效防范外 延式发展可能带来的风险。 应对措施：全面推进精准管理，提升效益。用管理手段解决发展问题，推动总部职能 部门的管理架构、流程与 IT 支撑的管理体系建设，打造营销体系及销售和服务平台、研 发体系和研发平台、制造和供应链平台、人力资源平台、财务平台，不断提升管理水平， 建立体系和组织竞争力。 应对措施：打造学习型组织、培训平台和工具体系，给予员工发展空间，逐步建立适 适用 □不适用 公司坚持国际化战略，快速发展海外市场，提升东富龙品牌的国际影响力，随着出口 业务占比日益增大，汇率的大幅变动可能对公司的经营业绩带来较大影响。 应对措施： ...